Strata Critical Medical, Inc.
$5.61
The Read: SRTA’s stock initially dipped about 3% after in-line Q4 2025 EPS amid a revenue decline but then surged over 30% following strategic refocus on medical logistics, a key acquisition, and in-line Q1 2026 EPS that boosted investor confidence.
Price
Overlays
Panel
SRTA
Hover to view data
No Data